On May, 8 CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s earnings release is anticipated by WallStreet, Faxor reports. Analysts predict 27.50 % diference or $-0.51 from the $-0.4 EPS from 2018. -29.17 % EPS growth is what Wall Street’s sees after $-0.72 reported EPS last quarter. Ticker’s shares touched $10.75 during the last trading session after 0.46% change.CytomX Therapeutics, Inc. has volume of 259,030 shares. Since April 15, 2018 CTMX has declined 64.48% and is downtrending. The stock underperformed the S&P 500 by 68.85%.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States.The company has $486.56 million market cap. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166.Currently it has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

For more CytomX Therapeutics, Inc. (NASDAQ:CTMX) news published recently go to: Globenewswire.com, Bizjournals.com, Globenewswire.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probodyâ„¢ Therapeutic Platform – GlobeNewswire” published on February 26, 2019, “Big Pharma trims projects — and a potential $1 billion in payments — from collaboration with small Peninsula biotech – San Francisco Business Times” on February 26, 2019, “CytomX Therapeutics Announces Senior Management Appointments Nasdaq:CTMX – GlobeNewswire” with a publish date: February 05, 2019, “Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for – Nasdaq” and the last “CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call – GlobeNewswire” with publication date: February 14, 2019.